Federal grant · project grant (b)
Continuous Liquid-liquid Extractors for Doubling of Productivity and Henhancement of Batch Based Drug Manufacturing - Project Summary/abstract Domestic Pharmaceutical Manufacturing Is Struggling to Meet Demands. It Is Therefore Imperative to Develop Tools to Rapidly Increase the Productivity of Existing Production Plants. Manufacturing of Pharmaceuticals Currently Relies Almost Entirely on Batch-based Chemical Synthesis. in This Approach, Chemical Synthesis Takes Place in Several Separate Steps Within Large Reactors. Synthesis in Continuous Flow (with Chemicals Flowing Continuously During the Reaction Process) Is Emerging as a More Efficient Alternative. However, Synthesis in Continuous Flow Is Not Being Widely Adopted Due to Several Practical Reasons, Including the Need for Major Investments to Overhaul Existing Production Plants. Liquid-liquid Extraction (LLE) Represents the Most Frequent Post-reaction Step in Pharmaceutical Syntheses. Importantly, While Technologies Currently Used for Lle in the Context of Batch Synthesis Are a Bottleneck That Dramatically Reduces Process Efficiency, Lle Extraction in Continuous Flow Is Highly Efficient. Existing Technologies for Lle in Flow Cannot Currently Be Used in Batch-based Manufacturing Plants Because Their Maximum Flow Rate Is Too Low to Meet the Demands of Batch-based Production Plants. Here, We Propose to Develop a Novel, High Capacity System to Implement Lle in Continuous Flow in the Context of Batch-based Pharmaceutical Synthesis. We Envision a Plug and Play, Portable, High Flow Rate, Self-tuning Device Deployable in Existing Pharmaceutical Production Plants Without the Need to Overhaul Production Processes. to Build This System, in the Phase I of This Sbir, We Have Addressed the Key Technological Innovations Needed to Enable the Proposed Innovation. in Phase Ii We Are Planning to Demonstrated Scalability of the Phase I Findings; Develop a Suitable Packaging Approach for Low Cost, Chemically Resistant Separation Modules; Build and Test in a Plant Facility a Complete, User-friendly High Capacity Continuous Lle System Compatible With Large-scale Batch-based Pharmaceutical Production. If Successful, This Project Will Produce a Tool Able to Immediately Increase the Productivity of Existing Pharmaceutical Plants From 2 to 5-FOLD. This Product Will Redefine the Landscape of Pharmaceutical Production in the United States and Beyond.
Committed
$1.5 Million
Paid out
$1.3M
84%
Committed, not yet paid
$242.1K
16%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.